This brand-new advocacy group is an unapologetic defender of high drug prices

The Alliance to Protect Medical Innovation, a new pharma advocacy group, is defending expensive list prices for prescription drugs.

The Alliance to Protect Medical Innovation, a new pharma advocacy group, is defending expensive list prices for prescription drugs. The group says its goal is to "help educate policymakers and the public about medical breakthroughs developed by the biopharmaceutical industry." An "About Us" section on its website describes it as a 501(c)(4) nonprofit. It is uncertain who funds the group or who is running its day-to-day operations. The group's website warns that insurers and PBMs are pushing "short-sighted policies that would disrupt the development of the cures and medicines that patients depend on." Ben Wakana, the executive director of Patients for Affordable Drugs, said in a statement the group "should disclose its funders immediately."